But first, what are Cannabinoids?
The reason this occurs is because the shape and chemical makeup of CBD and THC are very different. When CBD binds to receptors in the body, known as our CB1 receptors, it actually blocks THC from attaching to those same receptors in a first-come, first-serve manner. This reduces the psychoactivity of products that contain THC and can pave the way for the relaxing effects CBD is known for.
Products that are high in CBD and low in THC may be ideal for patients looking to keep a clear head, while getting some much-needed mind-body health benefits, including relief from stress, chronic pain, anxiety, insomnia, and more.
Stephen Hawking Kush offers mild, relaxing effects while doling out a healthy dose of CBD, too. This indica-dominant strain is one of the more unique CBD cuts out there, offering both heady and soothing effects.
CBD stands for cannabidiol, a non-intoxicating cannabis molecule with a variety of anecdotal and studied benefits. Strains high in CBD are popular with users for help with:
Bonus staff review: “This strain has become a household name among high-CBD strains. This variety tends to produce less than 1-2% of THC, so you can reap its medicinal benefits without the high. Sour Tsunami is fairly prolific, so keep an eye out for this strain at your next dispensary visit if you’re looking to quell pain or anxiety symptoms without the interference of THC.”
Cannatonic isn’t nearly as sedative as the name implies. This strain usually brings a smaller CBD/THC split, ranging from 5:1 down to 1:1. This even-keeled cannabinoid profile gives consumers a great deal of flexibility to use Cannatonic as medicine or as an enjoyable, mild mannered strain to unwind with.
Just as you can search for strains high in THC, sativa, or indica, you can also search for strains high in CBD – and Leafly users do just that.
Find Harlequin nearby
Sweet and Sour Widow lands in the middle ground with a 1:1 CBD/THC ratio. This even split offers first-time cannabis consumers an enjoyable entry point to both THC and CBD without sending them into orbit. It also makes for good medicine while being slightly euphoric and stoney.
Created by the larger-than-life grower and activist Lawrence Ringo, Sour Tsunami was brought into being by combining Sour Diesel and NYC Diesel. This unlikely pair of stimulating plants bred the high-CBD phenotype that has since redefined the medicinal qualities of cannabis.
Keywords: ACE2 receptor; CBD; COVID-19; SARS-CoV2; medical cannabis.
With the current COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an urgent need for new therapies and prevention strategies that can help curtail disease spread and reduce mortality. The inhibition of viral entry and thus spread is a plausible therapeutic avenue. SARS-CoV-2 uses receptor-mediated entry into a human host via the angiotensin-converting enzyme 2 (ACE2), which is expressed in lung tissue as well as the oral and nasal mucosa, kidney, testes and gastrointestinal tract. The modulation of ACE2 levels in these gateway tissues may be an effective strategy for decreasing disease susceptibility. Cannabis sativa, especially those high in the anti-inflammatory cannabinoid cannabidiol (CBD), has been found to alter gene expression and inflammation and harbour anti-cancer and anti-inflammatory properties. However, its effects on ACE2 expression remain unknown. Working under a Health Canada research license, we developed over 800 new C. sativa cultivars and hypothesized that high-CBD C. sativa extracts may be used to down-regulate ACE2 expression in target COVID-19 tissues. Using artificial 3D human models of oral, airway and intestinal tissues, we identified 13 high-CBD C. sativa extracts that decrease ACE2 protein levels. Some C. sativa extracts down-regulate serine protease TMPRSS2, another critical protein required for SARS-CoV-2 entry into host cells. While our most effective extracts require further large-scale validation, our study is important for future analyses of the effects of medical cannabis on COVID-19. The extracts of our most successful novel high-CBD C. sativa lines, pending further investigation, may become a useful and safe addition to the prevention/treatment of COVID-19 as an adjunct therapy.
CONFLICTS OF INTEREST: Pathway Rx and Swysh are startup companies engaged in medical cannabis and disease research.